Skip to main content

Table 2 Incidence rate of Treatment-Emergent Adverse Events, Serious Adverse Events and Adverse Drug Reactions

From: Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized Trial

 

Treatment group

(N = 27)

Comparator

(N = 31)

p-value

TEAEs [N, %]

[21, 77.78]

[24, 77.42]

0.974a

SAEs [N, %]

[3, 11.11]

[3, 9.68]

1.000b

ADRs [N, %]

[1, 3.70]

[0, 0.00]

0.466b

  1. TEAE Adverse event, SAE Serious Adverse Event, ADR Adverse Drug Reactions
  2. aChi-square test between treatment groups; bFisher’s exact test between treatment groups
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us